@article{fbfa63777431489b9e4bea48c74233d3,
title = "Brain morphometric correlates of metabolic variables in HIV: the CHARTER study",
abstract = "Obesity and other metabolic variables are associated with abnormal brain structural volumes and cognitive dysfunction in HIV-uninfected populations. Since individuals with HIV infection on combined antiretroviral therapy (CART) often have systemic metabolic abnormalities and changes in brain morphology and function, we examined associations among brain volumes and metabolic factors in the multisite CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) cohort, cross-sectional study of 222 HIV-infected individuals. Metabolic variables included body mass index (BMI), total blood cholesterol (C), low- and high-density lipoprotein C (LDL-C and HDL-C), blood pressure, random blood glucose, and diabetes. MRI measured volumes of cerebral white matter, abnormal white matter, cortical and subcortical gray matter, and ventricular and sulcal CSF. Multiple linear regression models allowed us to examine metabolic variables separately and in combination to predict each regional volume. Greater BMI was associated with smaller cortical gray and larger white matter volumes. Higher total cholesterol (C) levels were associated with smaller cortex volumes; higher LDL-C was associated with larger cerebral white matter volumes, while higher HDL-C levels were associated with larger sulci. Higher blood glucose levels and diabetes were associated with more abnormal white matter. Multiple atherogenic metabolic factors contribute to regional brain volumes in HIV-infected, CART-treated patients, reflecting associations similar to those found in HIV-uninfected individuals. These risk factors may accelerate cerebral atherosclerosis and consequent brain alterations and cognitive dysfunction.",
keywords = "Cholesterol, HIV, Metabolic, Neuroimaging, Obesity",
author = "Archibald, {S. L.} and McCutchan, {J. A.} and C. Sanders and T. Wolfson and Jernigan, {T. L.} and Ellis, {R. J.} and Ances, {B. M.} and Collier, {A. C.} and McArthur, {J. C.} and S. Morgello and Simpson, {D. M.} and C. Marra and Gelman, {B. B.} and Clifford, {D. B.} and I. Grant and C. Fennema-Notestine",
note = "Funding Information: B.B. GELMAN, MD, PhD—The author receives support from NIH Grants NS072005, MH79886, and HHSN271201000036C. Funding Information: The CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) study is supported by awards N01 MH22005, HHSN271201000027C, and HHSN271201000030C from the National Institutes of Health. The present study also was supported by National Institutes of Health grants P30 MH62512 (HIV Neurobehavioral Research Center, HNRC) and R01 MH79752. *The CHARTER group is affiliated with the Johns Hopkins University, Mount Sinai School of Medicine, University of California, San Diego, University of Texas, Galveston, University of Washington, Seattle, Washington University, St. Louis, and is headquartered at the University of California, San Diego, and includes Director Igor Grant, M.D.; Co-Directors Scott L. Letendre, M.D., Ronald J. Ellis, M.D., Ph.D., Thomas D. Marcotte, Ph.D.; Center Manager Donald Franklin, Jr.; Neuromedical Component Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D., Terry Alexander, R.N.; Laboratory, Pharmacology and Immunology Component Scott Letendre, M.D. (P.I.), Edmund Capparelli, Pharm.D.; Neurobehavioral Component Robert K. Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., Steven Paul Woods, Psy.D., Matthew Dawson; Virology Component Davey M. Smith, M.D. (P.I.), Joseph K. Wong, M.D.; Imaging Component Christine Fennema-Notestine, Ph.D. (P.I.), Michael J Taylor, Ph.D., Rebecca Theilmann, Ph.D.; Data Management Component Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman,; Statistics Component Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D.; Protocol Coordinating Component Thomas D. Marcotte, Ph.D. (P.I.), Rodney von Jaeger, M.P.H.; Johns Hopkins University Site Justin McArthur (P.I.), Mary Smith; Mount Sinai School of Medicine Site Susan Morgello, M.D. (Co-P.I.) and David Simpson, M.D. (Co-P.I.), Letty Mintz, N.P.; University of California, San Diego Site J. Allen McCutchan, M.D. (P.I.), Will Toperoff, N.P..; University of Washington, Seattle Site Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Trudy Jones, M.N., A.R.N.P.; University of Texas, Galveston Site Benjamin Gelman, M.D., Ph.D. (P.I.), Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., Mengesha Teshome, M.D. The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government. Some aspects of this study were presented at the Fourth International Meeting on HIV Infection and the Central Nervous System: Treating the Brain in the HAART Era. Frascati (Rome), Italy, July 2011. Funding Information: D.M. SIMPSON, MD—The author receives research support from the NIH (NINDS and NIMH). Funding Information: S. MORGELLO, MD—The author receives support from NIH grants U24MH100931, R25MH080663, and HHSN271201000036C. Publisher Copyright: {\textcopyright} 2014, Journal of NeuroVirology, Inc.",
year = "2014",
month = dec,
day = "12",
doi = "10.1007/s13365-014-0284-0",
language = "English",
volume = "20",
pages = "603--611",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
number = "6",
}